Fig. 2.

Tau pathology in male rTg4510 mice following doxycycline treatment. Representative immunohistochemical images of 4-, 8-, and 12-month-old male rTg4510 brains (a). RT-qPCR revealed a 40 to 50% reduction of tau expression in bi-transgenic rTg4510 (CC) mice receiving doxycycline (dox) treatment (b). Brain weight was decreased in CC mice at all time points, and was attenuated in 12-month-old CC + dox mice (c). Increasing levels of tau pathology were observed in both the hippocampus (d) and cortex (e) of CC mice from 8 months of age. These were normalised following doxycycline treatment. CC mice displayed high levels of atrophy in the hippocampus at all time points (f) and in the cortex at 8 and 12 months (g); atrophy was prevented by doxycycline treatment. Note that hashed lines do not represent longitudinal, repeated assessment of these animals. Scale bar = 500 μm. All data are presented as mean ± SEM. *p < 0.05, **p < 0.01, ***p < 0.001, versus wild-type/non-transgenic rTg4510 (WW) controls; ^# p < 0.05, ^## p < 0.01, ^###p < 0.001, versus rTg4510 CC mice